Cierra N. Sharp

576 total citations
17 papers, 423 citations indexed

About

Cierra N. Sharp is a scholar working on Pathology and Forensic Medicine, Public Health, Environmental and Occupational Health and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Cierra N. Sharp has authored 17 papers receiving a total of 423 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pathology and Forensic Medicine, 6 papers in Public Health, Environmental and Occupational Health and 4 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Cierra N. Sharp's work include Chemotherapy-induced organ toxicity mitigation (10 papers), Acute Lymphoblastic Leukemia research (6 papers) and Chronic Myeloid Leukemia Treatments (3 papers). Cierra N. Sharp is often cited by papers focused on Chemotherapy-induced organ toxicity mitigation (10 papers), Acute Lymphoblastic Leukemia research (6 papers) and Chronic Myeloid Leukemia Treatments (3 papers). Cierra N. Sharp collaborates with scholars based in United States and Canada. Cierra N. Sharp's co-authors include Leah J. Siskind, Levi J. Beverly, Mark A. Doll, Judit Megyesi, Tess V. Dupre, Parag P. Shah, Deanna Siow, Gavin E. Arteel, Mark W. Linder and Roland Valdes and has published in prestigious journals such as Neurology, The FASEB Journal and Journal of Lipid Research.

In The Last Decade

Cierra N. Sharp

15 papers receiving 418 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Cierra N. Sharp United States 10 227 160 115 60 54 17 423
Tess V. Dupre United States 10 129 0.6× 141 0.9× 85 0.7× 28 0.5× 34 0.6× 13 322
Kumiko Nishihara Japan 8 128 0.6× 136 0.8× 135 1.2× 34 0.6× 90 1.7× 8 452
Shanhua Mao China 12 131 0.6× 260 1.6× 82 0.7× 23 0.4× 54 1.0× 34 557
Mariellen Dentino United States 6 141 0.6× 72 0.5× 35 0.3× 33 0.6× 42 0.8× 8 354
Xiaoru Hu China 12 69 0.3× 194 1.2× 147 1.3× 19 0.3× 15 0.3× 29 480
Sujuan Xu China 13 44 0.2× 180 1.1× 110 1.0× 29 0.5× 14 0.3× 29 406
G.S. Reddy United States 16 578 2.5× 173 1.1× 48 0.4× 21 0.3× 42 0.8× 25 813
Daisuke Honda Japan 12 89 0.4× 213 1.3× 266 2.3× 11 0.2× 17 0.3× 30 609
Poonam Sansanwal United States 9 127 0.6× 72 0.5× 60 0.5× 26 0.4× 105 1.9× 11 415

Countries citing papers authored by Cierra N. Sharp

Since Specialization
Citations

This map shows the geographic impact of Cierra N. Sharp's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cierra N. Sharp with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cierra N. Sharp more than expected).

Fields of papers citing papers by Cierra N. Sharp

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cierra N. Sharp. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cierra N. Sharp. The network helps show where Cierra N. Sharp may publish in the future.

Co-authorship network of co-authors of Cierra N. Sharp

This figure shows the co-authorship network connecting the top 25 collaborators of Cierra N. Sharp. A scholar is included among the top collaborators of Cierra N. Sharp based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cierra N. Sharp. Cierra N. Sharp is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Sharp, Cierra N., et al.. (2023). Lung cancer-kidney cross talk induces kidney injury, interstitial fibrosis, and enhances cisplatin-induced nephrotoxicity. American Journal of Physiology-Renal Physiology. 324(3). F287–F300. 9 indexed citations
2.
Dupre, Tess V., Parag P. Shah, Mark A. Doll, et al.. (2022). Neutral ceramidase deficiency protects against cisplatin-induced acute kidney injury. Journal of Lipid Research. 63(3). 100179–100179. 11 indexed citations
3.
Sharp, Cierra N., et al.. (2020). ELISA-based detection of Open Reading Frame protein 1 in patients at risk of developing lung cancer. Clinica Chimica Acta. 507. 1–6. 3 indexed citations
4.
5.
Sharp, Cierra N., et al.. (2020). C57BL/6 mice require a higher dose of cisplatin to induce renal fibrosis and CCL2 correlates with cisplatin-induced kidney injury. American Journal of Physiology-Renal Physiology. 319(4). F674–F685. 33 indexed citations
6.
Sharp, Cierra N., Anita Fletcher, Penn Muluhngwi, et al.. (2020). A Shared Diagnostic Stewardship Approach toward Improving Autoimmune Encephalopathy Send-out Testing Utilization. The Journal of Applied Laboratory Medicine. 6(2). 387–396. 3 indexed citations
7.
Sharp, Cierra N., et al.. (2020). Newborn Drug Screening: Differential Outcome Using Meconium Versus Umbilical Cord Tissue. American Journal of Clinical Pathology. 154(Supplement_1). S2–S3.
8.
Lavasanifar, Afsaneh, et al.. (2019). Long interspersed nuclear element-1 mobilization as a target in cancer diagnostics, prognostics and therapeutics. Clinica Chimica Acta. 493. 52–62. 18 indexed citations
9.
Muluhngwi, Penn, et al.. (2019). Verification of Newly FDA-Approved Kappa and Lambda Free Light Chain Assays on a Previously Untested Platform. The Journal of Applied Laboratory Medicine. 4(3). 323–330. 5 indexed citations
10.
Sharp, Cierra N., Mark W. Linder, & Roland Valdes. (2019). Polypharmacy: a healthcare conundrum with a pharmacogenetic solution. Critical Reviews in Clinical Laboratory Sciences. 57(3). 161–180. 25 indexed citations
11.
Sharp, Cierra N., Mark A. Doll, Tess V. Dupre, Levi J. Beverly, & Leah J. Siskind. (2018). Moderate aging does not exacerbate cisplatin-induced kidney injury or fibrosis despite altered inflammatory cytokine expression and immune cell infiltration. American Journal of Physiology-Renal Physiology. 316(1). F162–F172. 13 indexed citations
12.
Sharp, Cierra N., et al.. (2018). Subclinical kidney injury induced by repeated cisplatin administration results in progressive chronic kidney disease. American Journal of Physiology-Renal Physiology. 315(1). F161–F172. 56 indexed citations
13.
Dupre, Tess V., Mark A. Doll, Parag P. Shah, et al.. (2017). Inhibiting glucosylceramide synthase exacerbates cisplatin-induced acute kidney injury. Journal of Lipid Research. 58(7). 1439–1452. 41 indexed citations
14.
Sharp, Cierra N. & Leah J. Siskind. (2017). Developing better mouse models to study cisplatin-induced kidney injury. American Journal of Physiology-Renal Physiology. 313(4). F835–F841. 87 indexed citations
15.
Dupre, Tess V., Mark A. Doll, Parag P. Shah, et al.. (2016). Suramin Protects From Cisplatin‐Induced Acute Kidney Injury. The FASEB Journal. 30(S1).
16.
Sharp, Cierra N., Mark A. Doll, Tess V. Dupre, et al.. (2016). Repeated administration of low-dose cisplatin in mice induces fibrosis. American Journal of Physiology-Renal Physiology. 310(6). F560–F568. 93 indexed citations
17.
Dupre, Tess V., Mark A. Doll, Parag P. Shah, et al.. (2015). Suramin protects from cisplatin-induced acute kidney injury. American Journal of Physiology-Renal Physiology. 310(3). F248–F258. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tess V. Dupre Breakdown of academic impact, for papers by Kumiko Nishihara Breakdown of academic impact, for papers by Shanhua Mao Breakdown of academic impact, for papers by Mariellen Dentino Breakdown of academic impact, for papers by Xiaoru Hu Breakdown of academic impact, for papers by Sujuan Xu Breakdown of academic impact, for papers by G.S. Reddy Breakdown of academic impact, for papers by Daisuke Honda Breakdown of academic impact, for papers by Poonam Sansanwal
Rankless by CCL
2026